Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QIAGEN (QGENF) - Star of Germany's Biotechs -- Ignore unavailable to you. Want to Upgrade?

To: D. K. G. who wrote (72)	11/7/2005 4:50:48 PM
From: tuck	Read Replies (1) \| Respond to of 122

H5N1 being a hot topic these days, this news might move QGEN a little: >>VENLO, THE NETHERLANDS--(MARKET WIRE)--Nov 7, 2005 -- QIAGEN N.V. (NasdaqNM:QGEN - News) (Frankfurt:QIA.F - News) (Prime Standard: QIA), a leading provider of solutions for molecular diagnostics today announced the global launch of two novel test kits for the detection of influenza and the avian flu virus (H5N1). These new and advanced tests for use in humans and animals expand the Company's current leading offering in this area and provide significant advantages: -- Breakthroughs in sensitivity and speed -- Broad detection of virus strains -- Integrated control mechanism to dramatically reduce false positives -- Most rapid molecular detection of H5 and H5N1 viruses -- under 75 minutes -- First and only avian flu PCR (H5N1) test for animals with government approval -- Most widely used test since 2004 for veterinary, export/import and food safety. The first newly added product is the artus(TM) Influenza/H5 kit. It combines a broad screening test, with a highly specific assay for the detection of characteristic nucleic acids (RNA) of avian flu (H5N1) virus strains. The highly sensitive test requires only small sample amounts of a patient's sputum, throat and nasal swabs, can detect an infection of influenza or avian flu (H5N1) virus in less than two hours and can be run on the widely available LightCycler instrument. The second kit added to the portfolio is a specific avian flu (H5N1) molecular detection kit targeting veterinary, import/export control and quarantine needs. This assay was launched in 2004 in China by PG Biotech. QIAGEN announced its agreement to acquire PG Biotech, a leading molecular diagnostics company in China in September of this year. This molecular test is worldwide the first product approved by a governmental authority specifically to detect avian flu (H5N1) in animals. It is believed to be by far the most widely used test kit for this purpose in the world. QIAGEN has also made available a number of protocols recommended by various government and other public sources to test for avian flu. These protocols have adopted QIAGEN components as the recommended and standard components. "The launch of these novel products and the breadth of our product portfolio for avian flu diagnosis demonstrate our commitment to providing the leading solutions for containing and treating pathogen-originated diseases such as avian flu," said Peer M. Schatz, QIAGEN's Chief Executive Officer. We invest heavily in scientific excellence and combine this with extensive experience working with governments, customers and regulatory agencies. The successful and first-to-market launches in these areas are proof of the strength of QIAGEN's innovation which continues to be the driver for our market and technology leadership in molecular diagnostics." "The availability of our rapid PCR-based molecular diagnostic solutions is critical at a time when fear of a pandemic may prompt individuals to rush into using anti-virals without having undergone the appropriate diagnosis. Physicians need precise information on the nature of an influenza infection when a patient presents with symptoms. Our tests will assist in determining the correct therapeutic strategy. We believe this is extremely important at a time when production of anti-virals may come under pressure as global demand increases," Dr. Joachim Schorr, Senior Vice President Global Research & Development added. "Due to the high mutation rate and diversity of the avian flu virus, broad detection of all H5 strains is very important and a significant feature to our new artus(TM) Influenza/H5 detection kit. Following validation by a renowned research institution, the kit will now be disseminated to leading international institutions. The Company intends to publish results in leading scientific journals shortly," said Dr. Ulrich Spengler, managing director of QIAGEN (Hamburg) GmbH. Product Information artus(TM) Influenza/H5 LC RT-PCR Kit QIAGEN's artus(TM) Influenza/H5 LC RT-PCR Kit combines a broad screening test (RealArt(TM) Influenza LC RT-PCR Kit) which detects all influenza A and B viruses with a highly specific detection of characteristic nucleic acids (RNA) of avian flu (H5N1) virus strains. The test comes in a ready to use master mix format and provides a fully integrated solution for avian flu detection when combined with QIAGEN's purification technology for virus, RNA QIAamp®. This combination and an integrated control system dramatically reduce the risk of false positives or negative results thus leading to increases in safety and reliability. During the development of the test the sequences of all H5N1 isolates known to date have been considered. The reliability of the general screening assay (RealArt(TM) Influenza LC RT-PCR Kit) for all influenza A and B viruses has been validated by several internal and external studies, using among others, samples from the Center for Disease Control and Prevention (CDC, Atlanta/USA). The artus(TM) Influenza/H5 LC RT-PCR Kit and RealArt(TM) Influenza LC RT PCR Kit are based on the real-time PCR technology. Both kits have been developed for the detection of influenza viruses in human samples using the LightCycler instrument. Contrary to the classical detection procedures for influenza viruses which require 7 to 14 days time for results, the specific and highly sensitive QIAGEN detection kit reduces the time to detection of the influenza or avian flu (H5N1) virus to less than two hours. The much shorter analysis time, in combination with highest levels of sensitivity and reliability, allows detection of the influenza virus at a very early stage. PG Biotech Avian influenza Virus FQ-PCR Detection Kit The highly efficient, sensitive and specific real-time PCR based kits can be used to detect Avian Influenza Virus in live poultry through anal and throat swabs, muscle or organ from dead animals, as well as serum or plasma samples. The Generic version of the real-time RT-PCR kit can detect all 15 subtypes (H1-H15) of Avian Influenza Virus A and is suitable for initial screening; the subtype H5, H7 and H9 specific versions can be used on generic tested positive samples subsequently to decide the viral subtypes. The real-time RT-PCR detection methods for Avian Influenza Virus, jointly developed by QIAGEN PG Biotech and Beijing Entry-Exit Inspection and Quarantine, recently approved as the new National Standards by the China State Bureau of Quality and Technical Supervision (CSBTS) and China Association for Standardization (CAS).<< snip Cheers, Tuck